Evidence-based cost-benefit analysis of Echinacea.
Echinacea purpurea, as part of a natural blend with Aronia melanocarpa and Lonicera caerulea extracts, shows potential in preventing and alleviating symptoms of upper respiratory tract infections (URTIs) due to its antiviral and immunomodulatory properties.
Individuals prone to URTIs or looking for natural alternatives to support immune health may benefit most from this supplement.
While Echinacea purpurea in combination with other extracts shows promise in URTI management, individual responses may vary. It is essential to consult a healthcare provider before starting any new supplement regimen, especially if you have existing medical conditions or are taking medications.
Compare other supplements by cost and evidence
Educational and research purposes only. Always consult a healthcare professional before starting any supplement regimen. ROI is modelled at $100,000 per quality-adjusted life year; see the methodology.